UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
ATLANTA, July 21, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that RYSTIGGO is commercially available for the treatment of adult patients in the U.S. with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
- ATLANTA, July 21, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that RYSTIGGO is commercially available for the treatment of adult patients in the U.S. with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
- RYSTIGGO was approved under Priority Review by the U.S. Food and Drug Administration (FDA) on June 26, 2023.2
RYSTIGGO is an HCP-administered injection, for subcutaneous use. - UCB also offers the "UCB Infusion Finder", an online search tool providing a non-exhaustive listing of approximately 1,000 infusion locations nationwide.
- RYSTIGGO will have options for infusion at multiple sites of care, including physicians' offices, hospital outpatient clinics, and independent infusion centers.